Metropolis Healthcare Posts Strong FY26 Results, Profit Jumps 31%

Metropolis Healthcare Ltd has announced its audited financial results for the fiscal year ended March 31, 2026, reporting significant increases in both profitability and revenue. The company also made key appointments and declared an interim dividend.

FY26 Financial Performance

For the fiscal year 2026, consolidated revenue from operations reached ₹1,645.85 crore, marking a substantial 22.28% increase from ₹1,346.32 crore in the prior fiscal year.

Profitability saw even stronger growth, with consolidated profit escalating by 31.39% to ₹191.18 crore. This compares to a profit of ₹145.51 crore recorded in FY25.

Dividend and Auditor Appointment

The Board of Directors approved the declaration of a second interim dividend for FY26, amounting to ₹1 per equity share.

In a significant governance move, Deloitte Haskins & Sells Chartered Accountants LLP has been appointed as the new statutory auditors for the company, securing a five-year term. This appointment follows a standard rotation cycle, succeeding M/s. B S R & Co. LLP.

Company Context and Management

Metropolis Healthcare operates as a prominent player within India's extensive diagnostic services sector, recognized for its broad network of centers. The company has actively pursued growth through network expansion and service portfolio enhancement.

A minor adjustment in senior management structure involves Dr. Nilesh Shah's transition to an advisory role, with his formal designation as Senior Management Personnel ending.

Key Risks and Investor Watchpoints

Investors are monitoring an ongoing Income Tax appeal before the Income Tax Appellate Tribunal (ITAT). This dispute relates to a demand of ₹3,880 lakh, a reduction from an initial ₹7,306.46 lakh, covering assessment years from 2014-15 to 2023-24. As of FY26, contingent liabilities linked to income tax appeals stood at ₹1,964.04 lakh.

Additionally, the company is assessing a potential incremental financial impact from the implementation of new Labour Codes, which has been categorized as an exceptional item.

Market Position

Metropolis Healthcare competes in a dynamic market against peers such as Dr. Lal PathLabs and Vijaya Diagnostic Centre. Its impressive 22.28% revenue growth in FY26 highlights strong performance within a sector experiencing consistent demand.

Future Outlook

Looking ahead, investors will focus on the outcome of the ITAT hearings concerning the tax demand. The finalization and accounting treatment of the new Labour Codes' impact will also be crucial. Furthermore, the performance and integration under the new auditors, Deloitte Haskins & Sells, will be closely watched, alongside the company's future expansion plans and efforts to improve operational efficiency.